About the CATIE trial for psychiatric Alzheimer symptoms
What is the CATIE Alzheimer trial?
available. In addition, the study team will coordinate care
CATIE (Clinical Antipsychotic Trials of Intervention
with the participant’s regular health care professional. Par-
Effectiveness) is a nationwide multicenter trial sponsored by
ticipants and their caregivers will also receive basic
the U.S. National Institute of Mental Health (NIMH). The
counseling, psychological support, advice on managing
goal of the CATIE Alzheimer’s disease trial is to compare
challenging behavior, education and skill development.
the effectiveness of four different medications in treating
delusions, agitation, aggression, hallucinations and other
Who may participate in this trial?
serious disruptions in thinking and behavior that may
Individuals with Alzheimer’s disease may be eligible to participate if they are experiencing one or more of the
occur in Alzheimer’s disease. The four study medications
are already approved by the U.S. Food and Drug
• Delusions or irrational ideas, such as believing that
Administration (FDA) to treat symptoms of major mental
“someone is out to get them” or that their caregivers
illnesses characterized by serious disruptions in individuals’
ability to perceive and interpret the world around them.
• Agitation — being restless or easily upset
• Physically or verbally aggressive behavior
Although symptoms of these mental illnesses are in some
• Hallucinations — seeing or hearing things that are not
ways similar to behavioral and psychiatric symptoms of
Alzheimer’s disease, few clinical studies have tested whether
Participants must also have a family member or caregiver
drugs used to treat these conditions are helpful for treating
available to accompany them to approximately 12 clinic
Alzheimer symptoms. Even fewer studies have directly
visits over nine months. With some exceptions, enrollees
compared the effectiveness of one of these drugs to the
will be allowed to continue taking medications for
Alzheimer’s disease and other health conditions. There are
study sites in Alabama, California, Connecticut, Florida,
The four drugs involved in this trial are olanzapine
Georgia, Hawaii, Illinois, Iowa, Louisiana, Maryland,
(Zyprexa ), quetiapine (Seroquel ), risperidone
Missouri, New Jersey, New York, North Carolina, Ohio,
(Risperdal ) and citalopram (Celexa ). The study is
designed so enrollees can try each medication until they
find the one that may be most helpful for them.
Where can I get more information?
Participants will initially be assigned to take one of the
To find a site near you or to request an information sheet
study drugs or a placebo (inactive treatment). After two
prepared by CATIE, please call our 24/7 Nationwide
weeks, those assigned to the placebo group will be assigned
Contact Center Helpline at 1.800.272.3900 or visit the
to one of the active treatments if they have not improved,
and enrollees who have not improved on one of the active
drugs may switch to another. As the trial progresses,
You may also call Karen Dagerman, CATIE Alzheimer’s
participants who improve on a study medication may stay
Disease Study project manager, at 1.323.442.3538 or e-mail her at [email protected]
on it, and those who do not benefit will be offered another
Information about the trial can also be accessed through the
Clinical Trials section of the Alzheimer’s Association Web
Study medications and related medical care will be
provided free, and transportation reimbursement is
2006 Alzheimer’s Association. All rights reserved.
CATIE Trial Page 1 of 2
This is an official publication of the Alzheimer’s Association but may be distributed by
unaffiliated organizations and individuals. Such distribution does not constitute an
endorsement of these parties or their activities by the Alzheimer’s Association.
The Alzheimer’s Association, the world leader in Alzheimer research, care and support, is dedicated to finding prevention methods, treatments and an eventual cure for Alzheimer’s. 24/7 Helpline 1.800.272.3900 TDD Access 312.335.8882 Web site www.alz.org e-mail [email protected]
Fact sheet updated January 28, 2003
2006 Alzheimer’s Association. All rights reserved.
CATIE Trial Page 2 of 2
This is an official publication of the Alzheimer’s Association but may be distributed by unaffiliated organizations and individuals. Such distribution does not constitute an endorsement of these parties or their activities by the Alzheimer’s Association.
Organic Chemistry II KEY February 14, 2008 1. Which of the following starting material/ reagent combinations would give rise to chlomiphene, a fertility agent? E 2. The major kinetic product(s) of the reaction of 2-methyl-2-pentene with Cl2, H2O is (are): A a) Organic Chemistry II KEY February 14, 2008 3. The major product of the reaction below is: B
Material Safety Data Sheet Date Prepared: 10/17/03 X-Gen Pharmaceuticals Prepared Technical Assistance: 607-562-2700 Big Flats, NY 14814 TRIAMCINOLONE ACETONIDE IDENTIFICATION Common Name: Triamcinolone Acetonide Chemical Name: Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1- methylethylidene)bis(oxy)]-, (11beta, 16alph